Pharmacological characterization of human incretin receptor missense variants

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 1, 2010, Pages 274-280

  Fortin, Jean Philippe ^a   Schroeder, Jonathan C ^a   Zhu, Yuantee ^a   Beinborn, Martin ^a   Kopin, Alan S ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE DEPENDENT INSULINOTROPIC POLYPEPTIDE RECEPTOR; HORMONE RECEPTOR; MUTANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; BINDING ASSAY; BIOASSAY; CELL SURFACE; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYO; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIGAND BINDING; LUCIFERASE REPORTER GENE ASSAY; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; REPORTER GENE; SIGNAL TRANSDUCTION; WILD TYPE;

CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTRIC INHIBITORY POLYPEPTIDE; GENES, REPORTER; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; LIGANDS; LUCIFERASES; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, GLUCAGON; TRANSFECTION;

EID: 73949123418     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160531     Document Type: Article

References (35)

1. Alewijnse AE, Smit MJ, Hoffmann M, Verzijl D, Timmerman H, and Leurs R (1998) Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem 71:799-807.
2. Al-Fulaij MA, Ren Y, Beinborn M, and Kopin AS (2008) Pharmacological analysis of human D1 AND D2 dopamine receptor missense variants. J Mol Neurosci 34:211-223.
3. Almind K, Ambye L, Urhammer SA, Hansen T, Echwald SM, Holst JJ, Gromada J, Thorens B, and Pedersen O (1998) Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells. Diabetologia 41:1194-1198.
4. Beinborn M, Ren Y, Bläker M, Chen C, and Kopin AS (2004) Ligand function at constitutively active receptor mutants is affected by two distinct yet interacting mechanisms. Mol Pharmacol 65:753-760.
5. Beinborn M, Worrall CI, McBride EW, and Kopin AS (2005) A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept 130:1-6.
6. Fortin JP, Zhu Y, Choi C, Beinborn M, Nitabach MN, and Kopin AS (2009) Membrane-tethered ligands are effective probes for exploring class B1 G proteincoupled receptor function. Proc Natl Acad Sci U S A 106:8049-8054.
7. Fulurija A, Lutz TA, Sladko K, Osto M, Wielinga PY, Bachmann MF, and Saudan P (2008) Vaccination against GIP for the treatment of obesity. PLoS One 3:e3163.
8. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, and Laburthe M (1995) Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 211:901-908.
9. Gault VA, McClean PL, Cassidy RS, Irwin N, and Flatt PR (2007) Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 50:1752-1762.
10. Gether U, Ballesteros JA, Seifert R, Sanders-Bush E, Weinstein H, and Kobilka BK (1997) Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility. J Biol Chem 272:2587-2590.
11. Hoare SR (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 10:417-427.
12. Hoare SR, Fleck BA, Gross RS, Crowe PD, Williams JP, and Grigoriadis DE (2008) Allosteric ligands for the corticotropin releasing factor type 1 receptor modulate conformational states involved in receptor activation. Mol Pharmacol 73:1371-1380.
13. 2+ signal transduction pathways. J Biol Chem 271:33382-33389.
14. Kazius J, Wurdinger K, van Iterson M, Kok J, Bäck T, and Ijzerman AP (2008) GPCR NaVa database: natural variants in human G protein-coupled receptors. Hum Mutat 29:39-44.
15. Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192.
16. Kim SJ, Winter K, Nian C, Tsuneoka M, Koda Y, and McIntosh CH (2005) Glucosedependent insulinotropic polypeptide (GIP) stimulation of pancreatic beta-cell survival is dependent upon phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB) signaling, inactivation of the forkhead transcription factor Foxo1, and down-regulation of bax expression. J Biol Chem 280:22297-22307.
17. KimWand Egan JM (2008) The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60:470-512.
18. Kubota A, Yamada Y, Hayami T, Yasuda K, Someya Y, Ihara Y, Kagimoto S, Watanabe R, Taminato T, Tsuda K, et al. (1996) Identification of two missense mutations in the GIP receptor gene: a functional study and association analysis with NIDDM: no evidence of association with Japanese NIDDM subjects. Diabetes 45:1701-1705.
19. Lee C, Gardella TJ, Abou-Samra AB, Nussbaum SR, Segre GV, Potts JT Jr, Kronenberg HM, and Jüppner H (1994) Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinology 135:1488-1495.
20. Lefkowitz RJ, Cotecchia S, Samama P and Costa T (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 14:303-307.
21. Lisenbee CS, Dong M, and Miller LJ (2005) Paired cysteine mutagenesis to establish the pattern of disulfide bonds in the functional intact secretin receptor. J Biol Chem 280:12330-12338.
22. Liu G, Fortin JP, Beinborn M, and Kopin AS (2007) Four missense mutations in the ghrelin receptor result in distinct pharmacological abnormalities. J Pharmacol Exp Ther 322:1036-1043.
23. Lovshin JA and Drucker DJ (2009) Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5:262-269.
24. Manhart S, Hinke SA, McIntosh CH, Pederson RA, and Demuth HU (2003) Structure-function analysis of a series of novel GIP analogues containing different helical length linkers. Biochemistry 42:3081-3088.
25. Mathi SK, Chan Y, Li X, and Wheeler MB (1997) Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. Mol Endocrinol 11:424-432.
26. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, et al. (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738-742.
27. Parthier C, Kleinschmidt M, Neumann P, Rudolph R, Manhart S, Schlenzig D, Fanghänel J, Rahfeld JU, Demuth HU, and Stubbs MT (2007) Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor. Proc Natl Acad Sci U S A 104:13942-13947.
28. Qi LJ, Leung AT, Xiong Y, Marx KA, and Abou-Samra AB (1997) Extracellular cysteines of the corticotropin-releasing factor receptor are critical for ligand interaction. Biochemistry 36:12442-12448.
29. Runge S, Thøgersen H, Madsen K, Lau J, and Rudolph R (2008) Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 283:11340-11347.
30. Samama P, Bond RA, Rockman HA, Milano CA, and Lefkowitz RJ (1997) Ligandinduced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. Proc Natl Acad Sci U S A 94:137-141.
31. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
32. Shinyama H, Masuzaki H, Fang H, and Flier JS (2003) Regulation of melanocortin-4 receptor signaling: agonist-mediated desensitization and internalization. Endocrinology 144:1301-1314.
33. Tibaduiza EC, Chen C, and Beinborn M (2001) A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem 276:37787-37793.
34. Tseng CC and Lin L (1997) A point mutation in the glucose-dependent insulinotropic peptide receptor confers constitutive activity. Biochem Biophys Res Commun 232: 96-100.
35. Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, and Froguel P (2000) Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106:253-262.